Drugs / LY3022855
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02718911 | Jun 2016 → Dec 2018 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02265536 | May 2015 → Nov 2017 | metastatic neoplasm, neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03101254 | Jun 2017 → Oct 2020 | melanoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3022855 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02265536 ↗ |
| Known as | IMC-CS4 | “LY3022855 (IMC-CS4)” NCT02265536 ↗ |
| Action | Inhibit | “CSF-1R inhibitor LY3022855” NCT02718911 ↗ |
| Modality | Monoclonal antibody | “with the mAb LY3022855.” PMID 32847933 ↗ Aug 2020 |
| Route | Intravenous | “treated with LY3022855 intravenously” PMID 32847933 ↗ Aug 2020 |
| Target | CSF1R | “LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor” NCT03101254 ↗ |